Fodder for an adaptive trial on both sides of the equation (escalate/de-escalate). Add cfRNA @max_diehn for response characterization at baseline? Excited about future trials and an informed adaptive landscape in HRNMIBC beyond initial risk stratification and blunt Rx. Lots of opportunities to potentially advance our treatments. swog 1602 publication should benchmark outcomes for design.
sciencedirect.com/science/articl…
Data from INSITE Yair Lotan at al. effect modification of utDNA on mBCG for #bladdercancer. Argument for BCG being therapeutic and not preventative. Very informative
1
1
7
783
Recommended reading materials prior to second opinions…. @dr_coops @uroegg @VickersBiostats @OtisBrawley (and of course the PCF new diagnosis pdf).
0
4
26
1,915
Pragmatic and timely design. Glad we have it in the portfolio.
.@MonikaJoshimd and @PGrivasMDPhD are leading #ClinicalTrial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemo in patients with advanced #UrothelialCancer. bit.ly/ea8231-study
0
1
4
380
Scott E Delacroix Jr M.D. retweeted
Found what was once the repository of all my medical knowledge while cleaning out the garage!
“Dad, what was clinical decision-making like before OpenEvidence?”
“Dad, what was clinical decision-making like before OpenEvidence?”
27
14
243
15,683
Scott E Delacroix Jr M.D. retweeted
@zklaassen_md @urotoday Also important (but ongoing): S2427 (BRIGHT) and NRG-GU015 (ARCHER)! #ESMO26
0
1
10
307
Scott E Delacroix Jr M.D. retweeted
DASL-HiCaP: darolutamide on top of 96 weeks of ADT plus RT improved MFS in very high-risk localized prostate cancer, HR 0.42, 4-yr MFS 95% vs 88%.
📈 n=1,106, interim at 67% of events, 46 mo follow-up. OS immature
📝 Thanks to @Silke_Gillessen putting this into context STAMPEDE D (HR 0.88): not contradictory, the ARPI benefit tracks metastatic risk
🎯 N1 is the clearest indication. N0 is less clear, and Gleason seems to matter
Every patient got pelvic RT, so who needs it in N0 not yet answered.
@Niazi_Dr7 #ProstateCancer #GUonc #ESMO26
📈 n=1,106, interim at 67% of events, 46 mo follow-up. OS immature
📝 Thanks to @Silke_Gillessen putting this into context STAMPEDE D (HR 0.88): not contradictory, the ARPI benefit tracks metastatic risk
🎯 N1 is the clearest indication. N0 is less clear, and Gleason seems to matter
Every patient got pelvic RT, so who needs it in N0 not yet answered.
@Niazi_Dr7 #ProstateCancer #GUonc #ESMO26
2
10
18
1,399
Scott E Delacroix Jr M.D. retweeted
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!
3
40
122
10,997
Scott E Delacroix Jr M.D. retweeted
JNJ-6143, first-in-class oral AR-BRD4 RIPTAC, phase 1 mCRPC: a wide window between efficacy and safety. n=105, doses 12.5 to 150 mg.
📈 50 mg daily: PSA50 77%, PSA90 48%, confirmed ORR 69%, after a median 4 prior lines
📊 PSA declines seen from 12.5 to 150 mg. 66% of all 🔍 At 50 mg: 58% any-grade TRAEs, no serious TRAEs. Median DOR 11.0 months, CI 5.9 to NE
Activity across a 12-fold dose range. Phase 2 is open at 50 mg.
Congrats to @BGarmezy on the presentation and all the investigators.
#ESMO26 #ProstateCancer #mCRPC #GUonc
📈 50 mg daily: PSA50 77%, PSA90 48%, confirmed ORR 69%, after a median 4 prior lines
📊 PSA declines seen from 12.5 to 150 mg. 66% of all 🔍 At 50 mg: 58% any-grade TRAEs, no serious TRAEs. Median DOR 11.0 months, CI 5.9 to NE
Activity across a 12-fold dose range. Phase 2 is open at 50 mg.
Congrats to @BGarmezy on the presentation and all the investigators.
#ESMO26 #ProstateCancer #mCRPC #GUonc
1
13
50
8,995
Scott E Delacroix Jr M.D. retweeted
Huge milestone as the ARCHER study hits 100 patients! 🎉
It’s evaluating if 5 sessions of high-dose SBRT can shorten radiation and preserve the bladder in MIBC.
Proud to share the explainer video we created to help explain the trial below!
primrmed.com/cancer-clinica…
It’s evaluating if 5 sessions of high-dose SBRT can shorten radiation and preserve the bladder in MIBC.
Proud to share the explainer video we created to help explain the trial below!
primrmed.com/cancer-clinica…
0
1
3
454
Scott E Delacroix Jr M.D. retweeted
Outstanding and provocative (🤩🤩on-brand) overview of advances in NMIBC from @DrMBWesterman #Shea26
0
9
13
1,576
Scott E Delacroix Jr M.D. retweeted
Meet the 2026–2027 SESAUA Board of Directors, led by President Paul W. F. Coughlin, MD, FACS. Thank you to our leaders for guiding the Section this year. sesaua.org/about/board-of… #SESAUA #Urology
0
3
7
573
@united what is going on with flight UA 2105 Supposed to be nola to hoston. Making circles over central Louisiana flying under 14,000 feet.
1
0
1
325
Scott E Delacroix Jr M.D. retweeted
🚨 #ARCHER @NRGonc GU 15 AMENDMENT
✅ Neoadjuvant and Adjuvant Therapy Explicitly Allowed
✅ TURBT→enrollment: 240 days with ≥3 NAT cycles
✅ Week-16 biopsy only if indicated
✅ Less frequent surveillance after year 2
✅ Local chemo/telehealth
✅ Updated adaptive RT/QA + utDNA 20 vs 5 fractions. #BladderCancer
#ASTRO26 @ASTRO_org
@UroCancer @drjefstathiou @SeanSachdevMD @ndesai2005 @l_ballas @IyerGopa @Dr_Aggen @shilpaonc @DrMBWesterman @Katie_Spina @MiyamotoDavid @AdityaBagrodia @jonathan_leeman @KashaniRojano @KateMRGuidance @abhiAsolanki
✅ Neoadjuvant and Adjuvant Therapy Explicitly Allowed
✅ TURBT→enrollment: 240 days with ≥3 NAT cycles
✅ Week-16 biopsy only if indicated
✅ Less frequent surveillance after year 2
✅ Local chemo/telehealth
✅ Updated adaptive RT/QA + utDNA 20 vs 5 fractions. #BladderCancer
#ASTRO26 @ASTRO_org
@UroCancer @drjefstathiou @SeanSachdevMD @ndesai2005 @l_ballas @IyerGopa @Dr_Aggen @shilpaonc @DrMBWesterman @Katie_Spina @MiyamotoDavid @AdityaBagrodia @jonathan_leeman @KashaniRojano @KateMRGuidance @abhiAsolanki
2
20
35
4,284
Scott E Delacroix Jr M.D. retweeted
Now published in Practical Radiation Oncology: @ASTRO_org's first clinical practice guideline on radiation therapy for bladder cancer!
The guideline supports trimodal therapy as a curative, bladder-preserving option for appropriately selected patients with muscle-invasive ifies radiation’s role after surgery and in advanced disease. Multidisciplinary care and shared decision-making are central throughout.
It was a privilege to co-chair this effort with Leslie Ballas and work with an exceptional multidisciplinary task force, our patient representative, and ASTRO staff. Thank you all for your expertise, collaboration, and dedication to improving bladder cancer care. A tremendous team effort!
Read more: bit.ly/4rcR77D
@ESTRO_RT
@Uroweb
#RadiationOncology #BladderCancer #OncoNews #RadOnc #PracticalRO #GUOncology
The guideline supports trimodal therapy as a curative, bladder-preserving option for appropriately selected patients with muscle-invasive ifies radiation’s role after surgery and in advanced disease. Multidisciplinary care and shared decision-making are central throughout.
It was a privilege to co-chair this effort with Leslie Ballas and work with an exceptional multidisciplinary task force, our patient representative, and ASTRO staff. Thank you all for your expertise, collaboration, and dedication to improving bladder cancer care. A tremendous team effort!
Read more: bit.ly/4rcR77D
@ESTRO_RT
@Uroweb
#RadiationOncology #BladderCancer #OncoNews #RadOnc #PracticalRO #GUOncology
1
13
41
2,758
Scott E Delacroix Jr M.D. retweeted
Wife: What did those LSU fans just say?! 😡 your son doesn’t need to hear that!
Me:
Me:
12
80
1,168
63,245
EVP MM? Magic-mushroom compound blocks a severe side effect of chemotherapy in mice nature.com/articles/d4158…
0
0
7
373